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ABSTRACT
Toxoplasmosis is an important parasitic infection of man and animals. It is well-known that the
progression and severity of disease depend on the immunological status of the host, but recent studies
suggest that the genetics of the parasite can also play a role. Diagnosis based on clinical appearance
and serology is not always easy. However, molecular methods do not depend on an immune
response, and allow direct detection of the parasite in biological samples. Thus they can be used to
establish a diagnosis when serological tests are not deﬁnitive. Multicopy sequences speciﬁc for
Toxoplasma gondii, e.g., the B1 gene or the 529-bp sequence, are especially useful in molecular tests.
Real-time PCR is very sensitive and is a promising technique that is capable of providing a
quantitative result. Molecular methods are also used for genotypic characterisation of T. gondii
isolates. Analysis of polymorphic sequences determines the precise strain. The choice of sequence is
critical when undertaking studies on the correlation between clinical signs and symptoms of disease
and the T. gondii genotype. Further studies involving direct genotyping of T. gondii from clinical
samples are needed.
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INTRODUCTION
Toxoplasma gondii is an obligate intracellular pro-
tozoan parasite that infects warm-blooded verte-
brates, including man. The parasite is distributed
widely in the human population, and is estimated
to affect more than a billion individuals world-
wide. Farm animals in the food chain are signi-
ﬁcant reservoirs of T. gondii, which is important
because of possible transmission to man, and
toxoplasmosis also causes signiﬁcant veterinary
losses.
Toxoplasmosis has a variable outcome,
depending on the interaction of many factors,
including the functions of the immune system.
Most infections are asymptomatic or take the
form of a mild, self-limiting illness. However, the
patient is left with life-long latent infection caused
by the presence of tissue cysts. The disease is
dangerous when contracted in utero, and also
for patients with immunodeﬁciency, especially if
adaptive immunity is involved (e.g., AIDS
patients, leukaemia patients, transplant patients).
Acute toxoplasmosis acquired during pregnancy
may result in fetal death or in serious complica-
tions such as blindness, deafness or central
nervous system disorders. These complications
may manifest in neonates, or later in life for
children infected congenitally.
Serological diagnosis can be difﬁcult in prenatal
cases or in patients with immunodeﬁciency. The
use of molecular diagnostic techniques is partic-
ularly appropriate for such patients, as these
techniques do not depend on the immunological
status of the host. However, although the immune
response plays a very important role in the
development of toxoplasmosis, several studies
have advanced the hypothesis that the outcome
and clinical presentation are also related to the
virulence of speciﬁc genotypes of T. gondii [1–3].
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LIFE-CYCLE AND VIRULENCE OF
T . GONDII
The life-cycle of T. gondii is well-established.
Sexual and asexual reproduction of the parasite
take place in the deﬁnitive hosts, which are all
members of the family Felidae (e.g., domestic
cats). In the asexual phase of the cycle (schizog-
ony), maternal cells divide to form daughter cells
termed merozoites. The sexual phase occurs in the
small intestine of a cat. The zygotes are formed in
epithelial cells and, after formation of a solid
wall, are discharged into the intestinal lumen as
oocysts. Sporulation occurs a few days after a cat
sheds oocysts. Sporulated oocysts are resistant to
adverse environmental conditions. Each oocyst
contains four sporozoites which are the invasive
form of T. gondii and remain infectious for
c. 1 year. Soil and plants contaminated with
oocysts are the source of infection for intermedi-
ate and deﬁnitive hosts. There is also evidence of
transmission as a consequence of drinking con-
taminated water [4,5].
In an intermediate host (e.g., man), T. gondii
undergoes an asexual phase in its life-cycle that
includes two forms, namely rapidly multiplying
tachyzoites and slowly multiplying bradyzoites.
Tachyzoites invade the host cells and are respon-
sible for the acute phase of the disease. Bradyzo-
ites, characterised by slow metabolic processes,
remain in the tissues as cysts. Tissue cysts can be
formed in many organs and tissues, e.g., brain,
heart and muscles, and these are the sources of
infection for carnivorous and scavenger interme-
diate and deﬁnitive hosts.
There are few opportunities in such a life-cycle
for genetic recombination through sexual repro-
duction (which requires infection in a cat with
two different toxoplasmas simultaneously), so the
population structure of T. gondii is of a clonal
type. Many pathogenic bacteria and protozoans
have such a population structure, with certain
clones being responsible for particular disease
patterns. In the case of T. gondii, such an associ-
ation is evident in animal models. For example,
there are T. gondii strains of high (type I) and low
virulence in mice. A single parasite of a virulent
strain forms an LD100 (a dose lethal for 100% of
animals tested), whereas an LD100 for a strain of
low virulence requires several thousand parasites
[5]. Interestingly, there have been no reports of
intermediate values, so the association between
strain and disease pattern in mice seems to be
clearly deﬁned. Similarly, in human foreskin
ﬁbroblast cultures, type I strains multiply three
times faster than parasites belonging to type II or
III. There have also been reports of different
immune responses in animal models against
different strains of T. gondii [6]. In addition,
virulent strains isolated from different hosts
comprise a single genetic lineage [1]. Thus, the
question arises as to whether there is a correlation
between the virulence factors of T. gondii and the
signs and symptoms of disease in man. If so,
could these virulence factors be used in the
development of tools to improve diagnosis, treat-
ment and prognosis? For example, could the
determination of T. gondii virulence factors con-
tribute to the development of new drugs or
vaccines?
Current studies on toxoplasmosis are focused
mainly on the use of molecular methods. Rapid
developments in molecular biology during recent
years have opened up new research possibilities,
with the advent of new technology often driving
the direction of research. The remainder of this
review describes the use of molecular techniques
in the diagnosis of toxoplasmosis.
IDENTIFICATION OF T . GONDII
WITH MOLECULAR TECHNIQUES
The presence of T. gondii in a biological sample
can be diagnosed by molecular techniques aimed
at detecting its genetic material. A speciﬁc frag-
ment of the genome can be ampliﬁed by PCR so
that it can be visualised on an agarose or a poly-
acrylamide gel following staining, on an auto-
mated sequencer by laser detection, or directly as
an ampliﬁcation product by means of real-time
PCR techniques. The sensitivity and speciﬁcity of
PCR-based methods depend on an appropriate
technique for isolation of genetic material from
samples, the characteristics of the DNA sequence
chosen for ampliﬁcation, and the parameters of
the ampliﬁcation reaction itself.
The ﬁrst stage in ampliﬁcation involves the
hybridisation of speciﬁc primers to a chosen
genome sequence. The sensitivity of the PCR is
enhanced if the target sequence exists in multi-
copies that are species-speciﬁc. For detection of
T. gondii, the sequence used most frequently is the
B1 gene, ﬁrst identiﬁed in 1998 by Burg et al. [7],
of which there are 35 copies in the genome. The
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function of this gene is not yet known, but its high
speciﬁcity is now well-established. In 2000,
Homan et al. [8] identiﬁed a 529-bp sequence,
also speciﬁc for T. gondii, which has over 300
copies in the genome. A comparison of methods
using the B1 and 529-bp sequences with real-time
PCR revealed a ten-fold improvement in sensi-
tivity when the 529-bp sequence was used [9].
Under speciﬁc conditions, the detection limit for
T. gondii genomic DNA was 200 fg for the B1
gene, compared to 20 fg for the 529-bp sequence.
The same study also investigated the speciﬁcity
obtained by detecting the 529-bp sequence in
clinical samples. The study tested ﬁve laboratory
strains of T. gondii, seven isolates of T. gondii from
amniotic ﬂuid, 51 amniotic ﬂuid samples from
patients in whom the presence of T. gondii had
been conﬁrmed previously, 160 assorted clinical
samples from patients without active toxoplas-
mosis (50% of these patients were seropositive for
T. gondii), and 118 assorted bacterial isolates.
Positive results were obtained only for isolated
strains of T. gondii and samples of amniotic ﬂuid
from patients with conﬁrmed toxoplasmosis.
Results were negative for all negative controls,
including samples from seropositive patients with
no clinical signs of toxoplasmosis. These results
indicate that methods based on detection of the
529-bp sequence should be applicable in the
clinical setting.
Other repetitive sequences include mobile gen-
etic elements (MGEs). There are 100–500 copies of
these per cell [10], but they are not completely
species-speciﬁc. MGE-PCR also allows the strain
type to be determined directly from specimens by
polymorphism analysis [11]. However, the MGE
method has not yet been tested widely, and its
possible use in the clinical setting requires fur-
ther investigation. Several other single-copy
sequences, including the SAG1, SAG2, SAG3,
SAG4 and GRA4 genes [12–15], have been used
as PCR targets in research laboratories.
The variety of ampliﬁcation methods in exist-
ence is explained, in part, by the fact that large
companies have shown little interest in making
test kits available commercially, with the result
that laboratories work largely with ‘home-made’
protocols. In an attempt to establish standardised
methodology, the EU BioMed 2 Programme
performed an anonymous test of protocols used
in 15 European laboratories [12]. The participating
laboratories were required to detect T. gondii in 12
‘artiﬁcial samples’ of amniotic ﬂuid (four negat-
ive, eight positive). Two laboratories identiﬁed all
samples correctly, while three laboratories failed
to detect the sample containing T. gondii at the
lowest concentration (one tachyzoite ⁄mL), with-
out any false-positive results. However, there
were also laboratories that failed to detect T. gondii
in any of the samples, and four laboratories
reported at least one negative control as positive.
There was no clear correlation between the
precise PCR methodology used and the results
obtained. Detailed analysis of the protocols did
not result in deﬁnitive recommendations, but in
general, the protocols involving the fewest separ-
ate procedures and handling steps seemed to give
the best results.
The absence of an accepted standard method
means that the sensitivity and speciﬁcity of
molecular tests cannot be compared in general
with those of conventional methods (e.g., sero-
logical testing, cell and animal cultures). Only
comparisons between particular protocols are
possible, and these appear to show the high value
of molecular tests [16–19], with the additional
advantage of the shorter time required to obtain a
result. The future for T. gondii diagnostics in the
short-term probably lies in the development of
tests based on real-time PCR, which also provide
a quantitative result and require fewer handling
steps. However, application of this technique is
limited at present because of the relatively high
costs of the necessary equipment.
GENOTYPING AND ANALYSIS OF
POPULATION STRUCTURE
The second step in the diagnosis of toxoplasmosis
involves identiﬁcation of the genetic group of
T. gondii involved. This could allow the degree of
pathogenicity of the parasite, including its viru-
lence, to be determined. Genotyping also has a
key role to play in studies of the population
biology of T. gondii and, in epidemiological
studies, in identiﬁcation of an infection source.
The potential correlation between genotype and
disease pattern may also be signiﬁcant from the
clinical viewpoint.
For studies in this area, the choice of method
for classifying the parasites into speciﬁc groups is
critical. Initial studies subdivided T. gondii iso-
lates on the basis of antigen [20–22] and isoen-
zyme [23,24] analyses. Other techniques have
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been used subsequently, including restriction
fragment length polymorphism (RFLP)-PCR ana-
lysis [22], random ampliﬁed polymorphic DNA
[25] analysis, and analysis based on sequence
length polymorphism [26]. Most recently, DNA
sequencing has allowed detailed and systematic
characterisation of speciﬁc genome fragments
[27–29].
According to the results of such studies, strains
of T. gondii can be divided into either two or three
different groups. Historically, as mentioned
above, three main genotypes have been recog-
nised, one of which is highly virulent while the
other two are of low virulence [1,2,30]. Isoenzyme
analysis allowed identiﬁcation of ﬁve groups
[31], but recent analyses of highly polymorphic
sequences, e.g., microsatellite sequences or
introns of genes, divide T. gondii strains into two
main genotypes [26,32,33]. However, most of
these methods cluster the highly virulent strains
together in a single group. The only exception is
random ampliﬁed polymorphic DNA analysis,
which clusters the virulent strains into closely
related groups [25].
Characterisation of T. gondii strains has been
based largely on RFLP analysis [1]. The method
uses the polymorphism associated with the pres-
ence or absence of restriction sites for speciﬁc
restriction enzymes. Thus, only a few random
variations are detected by this method. Single-
locus and multilocus RFLP analyses have been
performed. The SAG2 gene, which encodes the
tachyzoite surface antigen p22, is one of the more
commonly investigated loci. Other genes investi-
gated have included SAG1, SAG3, SAG4, ROP1
and B1 [2,34]. A large study byHowe and Sibley [2]
investigated 106 T. gondii isolates, mostly from
NorthAmerica andwestern Europe, by PCR-RFLP
of six loci. The isolates were derived from animal
and human samples (patients with congenital
toxoplasmosis or AIDS). After initial inoculation
into mice, followed by cell culture in human
foreskin ﬁbroblasts, T. gondii DNA was isolated
and RLFP analysis performed. The results indica-
ted that, with the exception of four isolates, all the
isolates comprised three clonal lineages. The four
exceptions appeared to have genotypes that were
recombinants of types I and III (one isolate) or
types II and III (three isolates). Most isolates
derived from human samples (congenital cases as
well as AIDS patients) belonged to the type II
genotype. Genotypes II and III were common
among samples from animals, while type I was
signiﬁcantly more common in human congenital
toxoplasmosis than in animals. The study sugges-
ted that a higher degree of parasitaemia inducedby
type I strains (as observed in mice) could increase
the risk of human transplacental transmission.
A further study on the population structure of
T. gondii was conducted on the basis of microsat-
ellite sequence analysis. Microsatellite sequences
are short tandem repeats of between two and six
nucleotides. Their polymorphism is caused by
different numbers of repeats in alleles, which
result in variable lengths. These sequences are
highly polymorphic and are consequently very
informative for genotyping and epidemiological
studies. To perform analysis of T. gondii isolates,
Ajzenberg et al. [26] chose eight microsatellite
sequences, at least ten nucleotides in length, since
a greater number of repeats corresponds to a
higher degree of polymorphism. It was possible to
identify a difference of two nucleotides in PCR
amplicon length by laser detection on an automa-
ted sequencer, which has a sufﬁciently high
resolution level to visualise such subtle differ-
ences. Among 84 isolates of both human and
animal origin, the number of alleles of speciﬁc
microsatellite sequences ranged from three to 16.
All of the isolates clustered into two main clonal
groups; the ﬁrst of these contained the virulent
isolates, while the second was more heterogene-
ous and contained not only avirulent isolates, but
also some isolates that had been identiﬁed by
isoenzyme analysis as atypical, and by PCR-RFLP
of the SAG2 gene as type I. In total, 74 genotypes
were recognised, thereby indicating a signiﬁcantly
greater discriminatory power for microsatellite
analysis than analysis based on isoenzymes (12
zymodemes among 86 isolates) [23] and six-loci
PCR-RFLP (15 genotypes among 106 isolates) [2].
The microsatellite method for genotyping
T. gondii isolates has been used to study the
correlation between T. gondii genotype and
human congenital toxoplasmosis [35]. In total, 86
isolates from amniotic ﬂuid, placenta, cord blood
and samples of fetal tissues or neonates in several
European countries (France, n = 82; Belgium,
n = 22; Italy, n = 1; and The Netherlands, n = 1)
were examined. Mouse inoculation or cell culture
was performed before isolation of DNA. Analysis
of eight microsatellite markers indicated that
most (89.7%) isolates belonged to the second
clonal group. Analysis of three microsatellite
Switaj et al. Molecular diagnostics for T. gondii infections 173
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 170–176
markers, b-tubulin, myosin A and EST (GeneBank
accession number W35487), associated with iso-
enzyme markers corresponding to the three rec-
ognised types, also indicated that most (85%)
isolates belonged to type II, while 8% belonged to
type I, 3% belonged to type III, and 4% belonged
to atypical genotypes.
The same study analysed the relationship
between clinical characteristics and genotypes of
T. gondii. Cases of severe toxoplasmosis resulted
from an infection in the ﬁrst weeks of pregnancy,
with resulting fetal or neonatal death, hydroceph-
alus, microphthalmia, ascites or neonatal hypo-
trophy. Infection of the mother between the 15th
and 38th weeks of pregnancy resulted in asymp-
tomatic or benign congenital toxoplasmosis
(isolated chorioretinitis, isolated intracranial cal-
ciﬁcation). Type II isolates were predominant in
the severe toxoplasmosis group, as well as in the
group of patients with benign and asymptomatic
toxoplasmosis. No T. gondii isolates belonging to
type I were associated with the benign and
asymptomatic toxoplasmosis patient group. There
were also four cases of maternal infection in the
second trimester, where T. gondii was detected in
placental tissues but the foetuses remained free
from infection. T. gondii isolates from these
samples belonged to type I. Three mothers were
treated with spiramycin throughout pregnancy,
and their children with a sulphonamide–pyri-
methamine combination. One mother and child
were not treated. All the children were seroneg-
ative at an age of 7–10 months. This is a very rare
observation, but as type I is an unusual T. gondii
type, it does not necessarily indicate a correlation.
While the explanation for the observation was not
clear, two hypotheses were suggested by the
authors of the study: (1) the foetuses were not
infected, perhaps because it is more difﬁcult for
type I tachyzoites to cross the human placenta
barrier; or (2) the foetuses were infected, but
because type I cysts contain fewer mature brad-
yzoites, they are more sensitive to treatment or an
immunological response, so that the cysts were
eliminated. These observations do not mean that
type I T. gondii strains are avirulent for foetuses
(since they were isolated from cases of severe
toxoplasmosis and were not found among isolates
derived from cases of benign toxoplasmosis), and
it does not mean that cysts of type I are always
eliminated (since type I isolates are observed in
cases of disease reactivation). Further studies on
congenital toxoplasmosis in experimental models
are needed to explain this ﬁnding.
The studies presented above were based on
T. gondii DNA isolated from parasites cultured in
cells or in animals, so that large amounts of highly
puriﬁed T. gondii DNA were obtained for analy-
sis. However, growth in mice or cell culture is
associated with a risk of possible artiﬁcial selec-
tion of virulent T. gondii isolates as a result of the
culture process. A few studies have therefore
involved direct genotyping on clinical samples. In
a typical study from Spain [36], T. gondii isolates
of type II were found to be predominant in
samples from AIDS patients, while type I was
predominant in samples from cases of congenital
toxoplasmosis. It is possible that the discrepancy
between the French and Spanish studies is asso-
ciated with the use of different methodology
(direct analysis vs. use of cell culture or mice), or
even with a geographical difference in the pre-
valence of the two different types.
Another study involving direct genotyping of
T. gondii examined vitreous ﬂuid specimens
obtained from 18 patients with ocular toxoplas-
mosis [34]. RFLP analysis of ﬁve loci revealed that
three samples contained a type I strain, and ﬁve
contained new recombinant genotypes; only one
strain of type III and three strains of type II were
identiﬁed. The study focused on patients with
severe or atypical toxoplasmosis, which could
have resulted in a strong bias toward virulent or
recombinant types. Analysis of only one locus
would have misidentiﬁed all ﬁve recombinant
strains, while analysis of three loci would only
have classiﬁed one strain incorrectly. It is possible
that analysis of other more polymorphic loci
would have identiﬁed even more novel recom-
binant genotypes.
The most precise molecular method of search-
ing for genetic polymorphism involves DNA
sequencing. Sequencing gives more systematic
information than RFLP analysis, so that precise
identiﬁcation of insertions ⁄deletions and substi-
tutions in the genome and rapid genotyping are
possible. A search for polymorphism in the
T. gondii population led to the analysis of introns.
These are the non-coding regions of genes, which
are generally more polymorphic than relatively
conserved coding exons. Sequencing of a 625-bp
intron in the DNA polymerase a gene of ten
reference strains separated the strains into two
lineages that corresponded with virulence [32].
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A further study, including more strains and
based on sequencing a 690-bp coding fragment of
the GRA6 gene, was performed by Fazaeli et al.
[27]. The GRA6 gene encodes the dense granule
antigen that is secreted by T. gondii and is
responsible for its survival within a cell. Poly-
morphism was detected in 24 different positions.
Two deletions of 15 and three nucleotides,
respectively, were characteristic of avirulent
strains. These mutations resulted in a protein
deletion of six amino-acids in type II strains. The
other polymorphic positions, with only one
exception, caused amino-acid substitutions in
the polypeptide chain encoded by GRA6. These
results indicated that this gene had relatively
high polymorphism in comparison with other
sequenced coding fragments from the SAG1,
SAG2 and GRA4 genes [14,15,37], and that it
was comparable to the polymorphism of the
hsp70 gene [28]. The hsp70 gene is present as a
single copy in the genome of T. gondii, and
encodes a cytoplasmic protein belonging to the
‘medium-molecular-mass’ heat-shock protein
family (68–78 kDa). Induction of hsp70 gene
expression is associated with bradyzoite devel-
opment and differentiation [38]. Expression of the
gene is signiﬁcantly higher in virulent than in
avirulent strains of T. gondii, and sequencing of
this gene revealed the presence of four copies of a
seven-amino-acid repeat unit (21 nucleotides in
length) at the 3¢-end in a virulent strain (RH),
compared to ﬁve copies in an avirulent strain
(ME49) [28].
There have been relatively few studies on
multiple T. gondii infections (with two or more
strains). Such infections seem to be highly prob-
able, as T. gondii is very common in nature. The
analysis is not very complicated, as T. gondii is
haploid, so that two different alleles in a sample
indicate two different strains. A study on mixed
infections in England and Wales performed RFLP
and sequence analyses of the SAG2 gene [29]. The
results of both analyses were in agreement and
indicated mixed infections (with type I and type II
strains) in ten of 32 samples. Six mixed infections
were demonstrated in samples from cases of
congenital toxoplasmosis. Other studies on mul-
tiple infections have been conducted with sam-
ples derived from commercial meat products [39]
and sheep [26], but further investigations on
mixed toxoplasmosis infections in man are
required.
CONCLUSIONS
Final identiﬁcation to the genotypic level is a result
of processes which, as indicated by the studies
outlined above, may be inﬂuenced by such factors
as primary growth in cell cultures or in animals,
the DNA isolation method or the target sequence
used for PCR. The variety of methods used for
T. gondii genotyping makes any meta-analysis
difﬁcult, so it is not yet established deﬁnitively
whether any correlation exists between toxoplas-
mosis in man and T. gondii virulence. As yet, there
are also no clear recommendations for routine tests
that could be applied at a clinical level. Further
studies with large numbers of patients, based on
direct analysis of genetic material by precise
methods such as real-time PCR and DNA sequen-
cing, are required for a greater understanding of
this important pathogen.
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